 0 Table of Contents |
  1 Home |
  2 Background |
  3 Cancerreport |
  4 Change Notes |
  5 Downloads |
  6 Specification |
  7 Artifacts Summary |
   7.1 Central Cancer Registry Reporting Pathology EHR Capability Statement |
   7.2 Pathology Laboratory Information System |
   7.3 US Pathology Bundle |
   7.4 US Pathology Composition Laboratory Report |
   7.5 US Pathology Diagnostic Report |
   7.6 US Pathology Observation |
   7.7 US Pathology Related Practitioner Role |
   7.8 US Pathology Service Request |
   7.9 US Pathology Specimen |
   7.10 Document DiagnosticReport Reference |
   7.11 CAP eCC Answer Codes |
   7.12 CAP eCC Form Codes |
   7.13 CAP eCC Question Codes |
   7.14 CAP eCC Section Codes |
   7.15 US Pathology Form Category Codes |
   7.16 US Pathology Provider Types |
   7.17 CAP eCC CodeSystem |
   7.18 US Pathology Code System |
   7.19 Additional Dimension Observation |
   7.20 Additional Findings Observation example |
   7.21 Additional Findings Section |
   7.22 Breast Biomarker Testing Performed on Previous Biopsy |
   7.23 Breast Specimen Example |
   7.24 Breast Tissue Excision Observation Example |
   7.25 Closest Margin(s) to Invasive Carcinoma example |
   7.26 Comments Section |
   7.27 Composition - Examination of Resection Specimens from Patients with Invasive Carcinoma of the Breast |
   7.28 Distant Metastasis Distant Site(s) Involved Observation example |
   7.29 Distant Metastasis Observation example |
   7.30 Distant Metastasis Section |
   7.31 Ductal Carcinoma In Situ Observation Example |
   7.32 Estrogen Receptor (ER) Status |
   7.33 General Tumor Site Observation |
   7.34 Glandular/Tubular Differentiation Observation Example |
   7.35 HER2 (by immunohistochemistry) |
   7.36 HER2 Observation Example |
   7.37 Histologic Grade Observation Example |
   7.38 Histologic Type Observation example |
   7.39 Lymph Nodes Section |
   7.40 Margin Distance from Invasive Carcinoma to Closest Margin example |
   7.41 Margin Status for Invasive Carcinoma Observation example |
   7.42 Margins Section |
   7.43 Mitotic Rate Observation Example |
   7.44 Next-of-Kin RelatedPerson example |
   7.45 Nuclear Pleomorphism Observation Example |
   7.46 Number of Sentinel Nodes Examined |
   7.47 Observation for Clock Position General |
   7.48 Oncologist Practitioner example |
   7.49 Oncologist PractitionerRole example |
   7.50 Overall Grade Observation Example |
   7.51 Pathologist Practitioner example |
   7.52 Pathology specimen collection procedure example |
   7.53 Patient example |
   7.54 Principal Pathology Lab example |
   7.55 PTNM Classification Observation example |
   7.56 pTNM Classification Section |
   7.57 Redwood Women's Center, P.C. example |
   7.58 Regional Lymph Nodes PT Category Observation example |
   7.59 Regional Lymph Nodes Section |
   7.60 Regional Lymph Nodes Status Observation example |
   7.61 Service Request - Cancer Pathology example |
   7.62 Special Studies Estrogen Receptor |
   7.63 Special Studies Section |
   7.64 Specific Clock Position Observation (8 o'clock) |
   7.65 Specimen Laterality Observation Example |
   7.66 Specimen Section |
   7.67 Surgeon Practitioner example |
   7.68 Surgeon PractitionerRole example |
   7.69 Total Number of Lymph Nodes Examined (sentinel and non-sentinel) example |
   7.70 Tumor Extent Observation Example |
   7.71 Tumor Focality Observation Example |
   7.72 Tumor Section |
   7.73 Tumor Size Observation |
   7.74 US Pathologist PractitionerRole example |
   7.75 US Pathology Breast Invasive Carcinoma DiagnosticReport example |
   7.76 US Pathology Encounter Specimen Collection example |
   7.77 US Pathology Exchange bundle example |